RW outcomes CD19 CAR Burkitt - 31 pts, 3 prior LOT, most axi-cel - 65% G3+ CRS, 19% G3+ ICANS - 16% D+28 mortality (!!!) - 6-mo CR 19%, mPFS 2.3 mos, mOS 6 mos - 3 pts who got post-CAR allo all relapsed Dismal outcomes & unmet need (BsAb? alloCAR?) #lymsm #ASH25 ashpublications.org/blood/articl...

Great to see another study w high efficacy of low-dose nivolumab (40mg Q2W; plus lenalidomide) in relapsed Hodgkin lymphoma: 90% ORR (60% CR, 30% PR), promising PFS & saturated PD1 receptor occupancy. Do we really need 240mg Q2W? www.sciencedirect.com/science/arti... @bloodjournals.hematology.org

Very happy to share our new Blood Spotlight Review on patterns of immune-related toxicities with anti-PD1 first-line treatment of Hodgkin lymphoma and remaining uncertainties @bloodjournals.hematology.org: doi.org/10.1182/bloo... Congrats to GHSG Physician Christian Jaworek for spearheading this!

Congrats @danielbachurski.bsky.social and everyone involved @uniklinikkoeln.bsky.social #CRC1530! Really great to see this exciting method and resulting mechanistic insights into immune remodelling in B-cell malignancies evolve over the last years and finally available as a Preprint.

Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm. Thanks David Russler-Germain + collabs aacrjournals.org/clincancerre...

Updated peer-reviewed evidence supports the safety and effectiveness of immunizations against Covid-19, RSV, and influenza during the 2025–2026 season @nejm.org @jakescottmd.bsky.social @stanforddeptmed.bsky.social www.nejm.org/doi/full/10....

A surprise bonus from COVID-19 vaccines: bolstering cancer treatment @science.org Patients who got shots of mRNA before starting a type of cancer immunotherapy lived much longer www.science.org/content/arti... on @nature.com www.nature.com/articles/s41...

Patient-centered and proportionate safety reporting in clinical trials is an EHA priority. Learn more about EHA's work in this recent HemaSphere Perspective: https://bit.ly/3JbBL1s

Patient- vs clinician-reported AEs from POLARIX @bloodjournals.hematology.org: - symptom incidence & severity much higher measured by PROs - sustained improvements in all QOL domains except cog functioning (worse R-CHOP arm) We must measure PROs in #lymsm trials! ashpublications.org/blood/articl...

A next-generation anti-CTLA-4 probody (folding the Fab fragment of the antibody in a tumor-associated protease-based manner) mitigates toxicity and enhances anti-tumor immunity in mice @natcomms.nature.com www.nature.com/articles/s41...

IFNγ-producing PD-1+ T cells are a potential key immune cell population mediating increased cardiovascular risk in patients with cancer receiving immune checkpoint inhibitor therapy @lunduniversity.bsky.social www.nature.com/articles/s44...

Eomes controls the acquisition of regulatory and cytotoxic function in CD4+ T cells that are critical for limiting immune toxicity, while maintaining persistence and tumor control after immunotherapy @cp-immunity.bsky.social www.cell.com/immunity/ful... @fredhutch.org

Cancer deaths expected to rise to over 18 million in 2050—an increase of nearly 75% from 2024, study forecasts. Explore the data ▶️ tinyurl.com/5n7dfnws @ihmeuw.bsky.social #NCDs

Congrats to my colleagues @unicologne.bsky.social, @uniklinikkoeln.bsky.social and @mpiage.bsky.social on their exciting study revealing functional synapses between neurons and small cell lung cancer. Out today @nature.com

Excited to share our preprint on the new HaJo cell line and robust systemic PDX in vivo model includin comprehensive characterization to enable further research in rare non-MCL B-cell lymphoma with CCND1 re-arrangement: www.biorxiv.org/content/10.1... @mpiage.bsky.social @uniklinikkoeln.bsky.social

A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR T-cell therapy. Read the full case details: nej.md/41fYX4v #MedSky #Hematology #Genetics

Honoured to have contributed a @bloodjournals.hematology.org Commentary (doi.org/10.1182/bloo...) on a recent study by @drmiguelperales.bsky.social @mskcancercenter.bsky.social highlighting improved outcomes with alloSCT in r/r cHL after prior ICI exposure (doi.org/10.1182/bloo...)

Longitudinal measurement of serum TARC shows rapid early cHL response to first-line nivolumab monotherapy and N-AVD. Potential to guide individualized immunotherapy? Great collaboration with W. Plattel @rug.nl now published @hemasphere-journal.bsky.social: onlinelibrary.wiley.com/doi/epdf/10....

Great to see the results of a joint NLG x GHSG academic phase 2 trial @hemasphere-journal.bsky.social: First-line treatment with B-CAP is feasible and effective in older patients with advanced-stage cHL, with improvement of most patient-reported HRQoL domains onlinelibrary.wiley.com/doi/10.1002/...

📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx. #DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines 🔗 buff.ly/2ZYJc2c

Review @cp-med.bsky.social Immune-related adverse events associated with cancer immunotherapy www.cell.com/med/abstract...

In a patient with pathogenic ZAP70 mutations and HPV19-integrated SCC, restoring T-cell receptor signaling by stem-cell transplantation resolved HPV-related disease, revealing a direct oncogenic role for β-HPV in immunodeficiency. Read the Brief Report: nej.md/4lTiTCC #MedSky

Our analysis of the HD21 Older Cohort is now published in the JCO @ascocancer.bsky.social doi.org/10.1200/JCO-... @ferdinandusj.bsky.social 🎉 Key take away: PET-guided 4-6x BrECADD is feasible and highly effective in older AS-cHL patients 60-75 years of age, thereby expanding treatment options 🧵👀👇

#NatMetabPicks | In Cancer Discovery @aacrjournals.bsky.social, L Zitvogel, C Bigenwald et al (@gustaveroussy.fr) Oral supplementation with Akkermansia spp. Improves the efficacy of CAR-T cells against B cell lymphoma. 🧪 aacrjournals.org/cancerdiscov...

By integrating multi-dimensional data with deep learning, a new method known as ImmuScope predicts both MHC-II presentation and T helper cell immunogenicity @natmachintell.nature.com www.nature.com/articles/s42... www.nature.com/articles/s42...

Structural variations disrupting the 3’-UTR of PD-L1 and high PD-L1 expression were related with response to this combination therapy. buff.ly/9mWJEMH #hemesky

Really good to see improved gonadal function recovery and child birth rates after 4-6x BrECADD vs eBEACOPP in advanced-stage HL. Results now published are further supporting BrECADD as preferred treatment: @thelancetoncol.bsky.social doi.org/10.1016/S147... Congrats to the international HD21 team.

Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy @jci-insight.bsky.social insight.jci.org/articles/vie...

3-year follow-up of TRANSFORM @ascocancer.bsky.social confirms significantly improved PFS with lisocel compared to SOC as second-line treatment for r/r LBCL (51% vs 26%): ascopubs.org/doi/10.1200/... PRO indicate improved HRQoL incl. Fatigue on treatment with lisocel, but similar long-term outcomes.

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results and Research Summary: nej.md/4mh5RPL #MedSky

Congrats to Daniel Bachurski @uniklinikkoeln.bsky.social on a very nice, comprehensive review @febsletters.bsky.social on biological and technical approaches to study extracellular vesicles in B-cell malignancies. Rapid progress & unprecedented insights: febs.onlinelibrary.wiley.com/doi/epdf/10....

A Double Take video reviews the risk factors for acute heat-related illnesses, along with clinical features, complications, and management, and discusses preventive guidelines and measures. Watch now: nej.md/3zjVyq9 #MedSky #ClimateChange

“The combination of glofitamab with R-CHOP or Pola-R-CHP is deliverable and results in high rates of durable response in this population of younger patients with high-burden supporting its ongoing exploration as a [first-line] treatment “ ascopubs.org/doi/10.1200/... ascopost.com/news/july-20...

I would encourage everyone to read this open-access article from @thelancet.com, which analyzes the impact of #USAID funding and estimates that the cut in funding by the Trump administration will lead to FOURTEEN MILLION EXCESS DEATHS IN THE NEXT FIVE YEARS. www.thelancet.com/journals/lan...

Impressive, thought provoking preprint (arxiv.org/pdf/2506.22405) by a Microsoft AI team: Much higher diagnostic accuracy (80% vs 20%) and 20% lower costs with iteratively thinking "MAI Diagnostic Orchestrator" vs Generalist Physicians. Elegant study building on >300 @nejm.org case reports.

Presented at the #ADASciSessions: Zimislecel is an allogeneic stem cell–derived islet-cell therapy. This phase 1–2 study supports the hypothesis that zimislecel can restore physiologic islet function and thus treat persons with type 1 diabetes. Full study results: nej.md/3ZGupbv

inMIND tafa-R2 RCT in R/R FL #18ICML - 548 pts, 50% FLIPI 3-5, 32% POD24 - mPFS 22 mos (v 14 mos) with tafa - benefit seen with tafa in POD24 subgroup - superior TTNT, no diff OS, more deaths pbo arm - no HT events with tafa, multiple seen w/ pbo Now FDA approved in FL! #lymsm

Online Now: Large B cell lymphoma microenvironment archetype profiles

Was also impressed with (short-term) efficacy after presentation at #EHA2025, which curiously seems to be dose-independent. My understanding after Q&A at EHA was that there are currently no plans to develop it further?

MyLymphoma App Alliance officially launched at #ICML2025: 3 mobile apps to collect patient experiences during and after lymphoma treatment. #lymsm @judithtrotman.bsky.social @janfalconer.bsky.social learn more at myhodgkinmyhealth.com

Online Now: CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma

First session of #18ICML: MyLymphoma apps to collect disease, treatment and patient-reported outcomes directly from patients. WhiMSICAL set the stage in WM, now with MyHodgkin MyHealth and FOLLowed for Life. #lymsm @judithtrotman.bsky.social @icmlugano.bsky.social

6x Nivo-AVD with PFS & OS benefit and better tolerability vs 6x BV-AVD in AS-HL pts ≥60 years in the randomised S1826 trial. Efficacy driven by EBV status? PRO-CTCAE confirming better tolerability & revealing discrepancy to physician reporting @ascocancer.bsky.social ascopubs.org/doi/10.1200/...

Rilzabrutinib acts through multi-immune modulation mechanisms targeting key aspects of ITP disease pathophysiology. buff.ly/2y1gxnZ #hemesky

#18ICML does not only feature exciting new data across lymphomas presented at one of the most beautiful conferences, but a great Educational: onlinelibrary.wiley.com/toc/10991069... Recommend the evaluation of T-cell redirecting strategies by Gloria Iacoboni onlinelibrary.wiley.com/doi/full/10....

Getting ready for the Hematology in Focus Session on Hodgkin Lymphoma at #EHA2025 ☕️🥐🇮🇹 Join us in Gold Hall at 8am to discuss the exciting developments in the field.

If you want to hear more from the authors of the first set of commission manuscripts, our @thelancethaem.bsky.social podcast is now online! www.buzzsprout.com/1564352/epis... ft @biostatgirl.bsky.social @broeckelmann.bsky.social #EHA2025 #EHA25

Heartfelt congrats to David, Roland and the whole @uniklinikkoeln.bsky.social lymphoma team! Great to see our exciting study on targeting CSF1R+ myeloid-monocytic cells to overcome CAR-T cell resistance now published online in Cancer Cell @cp-cancercell.bsky.social: doi.org/10.1016/j.cc... 🎉

Join us today at 2pm for an exciting joint EHA-EMA session on modernising tolerability assessment at #EHA2025 in Milan!

‼️ #ASCO25 #JCOOP simultaneous publication by Velez et al:  Adequacy of Immune Checkpoint Inhibitor-Associated Thyroid Function Monitoring Following Therapy. Read the full article: brnw.ch/21wT6ov